Neochem Bio Solutions Ltd

Q3 FY26Chemicals & Petrochemicals

Neochem Bio Solutions Q3 FY26 investor presentation: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹111

Market cap₹191 Cr

P/E15.3

Updated16 Oct 2026

Read4 min read

Based on Neochem Bio Solutions Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.

The short version

Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. EBITDA for Sept’25 quarter: ₹859.22 Lakh, up from ₹422.84 Lakh in FY23 (approx.

From Neochem Bio Solutions Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh.
This represents a year-on-year growth from ₹4,818.84 Lakh in FY23 to ₹6,114.63 Lakh in FY24, ₹8,417.27 Lakh in FY25, showing a 32.16% CAGR projected for FY23–25.
EBITDA for Sept’25 quarter was ₹859.22 Lakh, up from ₹422.84 Lakh in FY23.
PAT for Sept’25 was ₹548.38 Lakh, compared to ₹107.29 Lakh in FY23.
The presentation projects revenue of ₹8,417.27 Lakh for FY25 continuing growth.
Volume or sales quantity figures are not explicitly stated.

2 more points from Neochem Bio Solutions Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

EBITDA for Sept’25 quarter: ₹859.22 Lakh, up from ₹422.84 Lakh in FY23 (approx. 103% increase YoY from FY23 annual figure)
EBITDA Margin for Sept’25 quarter: 18.75%, improved from 8.77% in FY23
Profit After Tax (PAT) for Sept’25 quarter: ₹548.38 Lakh, up from ₹107.29 Lakh in FY23 (approx. 411% increase YoY from FY23 annual figure)

2 more points from Neochem Bio Solutions Ltd's call on margins

Pro opens every point from 15K+ earnings calls

See what Neochem Bio Solutions Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Existing manufacturing facility at Moraiya, Ahmedabad:
Installed capacity: 22,000 MTPA
Capacity utilization in FY25: 41.82%
Land holding of 60,995 sq. mt at Dholka (page 6), indicating potential for future expansion, but no explicit new plant or project details provided.
No specific capital expenditure (capex) amounts, new plant constructions, or expansion timelines detailed in the presentation.
The presentation highlights in-house R&D and a zero liquid discharge (ZLD) facility supporting sustainability but does not specify capex or timeline for upgrades.

- Manufacturing process description and capacity utilization data suggest focus on optimizing existing facility rather than imminent new capacity addition. - The company’s strategy emphasizes expansion of geographical presence and partnerships rather than facility expansion presently. In summary, the presentation does not specify any new capex projects, new plants, or concrete capacity expansion plans with amounts or timelines.

2 more points from Neochem Bio Solutions Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked

1Shiv Texchem Ltd₹265 Cr

Rev 1Mar 2

2Kiri Industries Ltd₹3.3K Cr

Rev 1Mar 3

3₹1.8L Cr

Rev 2Mar 1

4₹48.4K Cr

Rev 2Mar 1

5₹3.4K Cr

Rev 2Mar 1

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation indicates fundraising through equity, as the share capital increased from ₹542.60 Lakh (FY23) to ₹1,253.20 Lakh (Sept’25), and reserves and surplus grew from ₹262.54 Lakh to ₹1,970.46 Lakh in the same period, reflecting equity infusion.
There is a notable increase in short-term borrowings from ₹1,383.05 Lakh (FY23) to ₹2,517.17 Lakh (Sept’25), indicating higher debt levels in the short term.
Long-term borrowings decreased from ₹1,811.81 Lakh (FY24) to ₹1,336.54 Lakh (Sept’25), showing some repayment or refinancing of long-term debt.
The Debt to Equity ratio shows fluctuations: 2.78 (FY24), rising to 6.64 (FY25), then reducing to 4.52 (Sept’25), implying changes in leverage.

2 more points from Neochem Bio Solutions Ltd's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Neochem Bio Solutions Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention or provide details on the company's order book, order inflow, or pending orders. There is no direct information or data regarding current orders, backlog, or order inflow status in the document. The presentation focuses on financials, business strategies, investment rationale, manufacturing capacity, product formulations, geographical presence, leadership, sustainability initiatives, and certifications, but does not disclose specifics about order volumes or pending orders.

What Neochem Bio Solutions Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Thirumalai Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran
Jubilant Agri & Consumer Products Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations: INR 4,510 million, up 13% YoY from INR 3,975 million in Q3 FY25 (Page 20). Key investor presentation takeaways from Jubilant Ag
Chemfab Alka. (Q3 FY26)
Revenue from Operation: ₹62.17 crore, down 21.51% YoY (₹79.21 crore in Q3FY25) . Key investor presentation takeaways from Chemfab Alka.'s Q3 FY26 investor prese
Galaxy Surfactants Ltd (Q3 FY26)
. Key concall takeaways from Galaxy Surfactants Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Solar Industries vs SRF Ltd vs Linde India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Neochem Bio Solutions Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Neochem Bio Solutions Ltd Q3 FY26 results?

Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. EBITDA for Sept’25 quarter: ₹859.22 Lakh, up from ₹422.84 Lakh in FY23 (approx.

What is Neochem Bio Solutions Ltd share price analysis?

Neochem Bio Solutions Ltd currently shows a neutral. The stock trades at a P/E of 15.3 with a market cap of ₹191 Cr. Investors should review the full earnings analysis for detailed insights.

Is Neochem Bio Solutions Ltd planning capital expenditure?

Existing manufacturing facility at Moraiya, Ahmedabad: - Installed capacity: 22,000 MTPA - Capacity utilization in FY25: 41.82% - Land holding of 60,995 sq.

Keep Neochem Bio Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Revenue & Sales Performance

Profitability & Margins

Capital Expenditure Plans

Top-ranked in Chemicals & Petrochemicals

Fundraising & Capital Structure

Order Book & Pipeline

Continue your research

What Neochem Bio Solutions Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Neochem Bio Solutions Ltd and 15K+ more earnings calls,for less than your morning chai

Frequently Asked Questions

Neochem Bio Solutions Ltd and 15K+ more earnings calls,
for less than your morning chai